Market Cap
US$25.3b
Last Updated
2020/08/11 00:20 UTC
Data Sources
Company Financials +
Executive Summary
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases.
Snowflake Analysis
Outstanding track record with adequate balance sheet.
Similar Companies
Share Price & News
How has ResMed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RSMD.F has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-16.5%
RSMD.F
-1.4%
US Medical Equipment
1.2%
US Market
1 Year Return
n/a
RSMD.F
14.9%
US Medical Equipment
16.8%
US Market
Return vs Industry: Insufficient data to determine how RSMD.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how RSMD.F performed against the US Market.
Shareholder returns
| RSMD.F | Industry | Market | |
|---|---|---|---|
| 7 Day | -16.5% | -1.4% | 1.2% |
| 30 Day | -14.5% | 7.8% | 4.9% |
| 90 Day | n/a | 11.7% | 20.0% |
| 1 Year | n/a | 15.9%14.9% | 19.3%16.8% |
| 3 Year | 142.2%142.2% | 72.7%68.1% | 43.7%34.4% |
| 5 Year | 208.0%208.0% | 116.8%100.0% | 75.5%56.6% |
Price Volatility Vs. Market
How volatile is ResMed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is ResMed undervalued compared to its fair value and its price relative to the market?
40.67x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: RSMD.F ($17.8) is trading above our estimate of fair value ($17.41)
Significantly Below Fair Value: RSMD.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RSMD.F is good value based on its PE Ratio (40.7x) compared to the US Medical Equipment industry average (51.9x).
PE vs Market: RSMD.F is poor value based on its PE Ratio (40.7x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: RSMD.F is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: RSMD.F is overvalued based on its PB Ratio (10.2x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is ResMed forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
9.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RSMD.F's forecast earnings growth (9.5% per year) is above the savings rate (2.2%).
Earnings vs Market: RSMD.F's earnings (9.5% per year) are forecast to grow slower than the US market (23.7% per year).
High Growth Earnings: RSMD.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: RSMD.F's revenue (7% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: RSMD.F's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RSMD.F's Return on Equity is forecast to be high in 3 years time (24.1%)
Next Steps
Past Performance
How has ResMed performed over the past 5 years?
9.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RSMD.F has high quality earnings.
Growing Profit Margin: RSMD.F's current net profit margins (21%) are higher than last year (15.5%).
Past Earnings Growth Analysis
Earnings Trend: RSMD.F's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: RSMD.F's earnings growth over the past year (53.6%) exceeds its 5-year average (9% per year).
Earnings vs Industry: RSMD.F earnings growth over the past year (53.6%) exceeded the Medical Equipment industry 1.2%.
Return on Equity
High ROE: RSMD.F's Return on Equity (24.9%) is considered high.
Next Steps
Financial Health
How is ResMed's financial position?
Financial Position Analysis
Short Term Liabilities: RSMD.F's short term assets ($1.5B) exceed its short term liabilities ($602.8M).
Long Term Liabilities: RSMD.F's short term assets ($1.5B) exceed its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: RSMD.F's debt to equity ratio (47.1%) is considered high.
Reducing Debt: RSMD.F's debt to equity ratio has increased from 19.2% to 47.1% over the past 5 years.
Debt Coverage: RSMD.F's debt is well covered by operating cash flow (68.2%).
Interest Coverage: RSMD.F's interest payments on its debt are well covered by EBIT (20.6x coverage).
Balance Sheet
Next Steps
Dividend
What is ResMed current dividend yield, its reliability and sustainability?
0.89%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: RSMD.F's dividend (0.89%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.62%).
High Dividend: RSMD.F's dividend (0.89%) is low compared to the top 25% of dividend payers in the US market (4.35%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, RSMD.F has been paying a dividend for less than 10 years.
Growing Dividend: RSMD.F's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (36.2%), RSMD.F's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: RSMD.F's dividends in 3 years are forecast to be well covered by earnings (31.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.4yrs
Average management tenure
CEO
Mick Farrell (48 yo)
7.42yrs
Tenure
US$9,635,100
Compensation
Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, serves as the Chief Executive Officer of ResMed Pty Ltd. Mr. Farrell has been the Chief Executive Officer of ResMed Inc. since March 1, 2013. Mr. Fa ...
CEO Compensation Analysis
Compensation vs Market: Mick's total compensation ($USD9.64M) is about average for companies of similar size in the US market ($USD11.30M).
Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Non-Executive Chairman | 6.58yrs | US$791.18k | 0.16% $ 39.6m | |
| CEO & Director | 7.42yrs | US$9.64m | 0.25% $ 63.7m | |
| President & COO | 7.42yrs | US$6.43m | 0.15% $ 36.8m | |
| Chief Financial Officer | 14.58yrs | US$2.91m | 0.059% $ 14.9m | |
| President of Sleep & Respiratory Care Business | 9.25yrs | US$3.27m | 0.060% $ 15.3m | |
| President of Software as a Service Business (SaaS) | 3.08yrs | US$2.93m | 0.020% $ 5.0m | |
| Chief Technology Officer | 2.33yrs | no data | no data | |
| Chief Administrative Officer | 9.25yrs | US$2.72m | 0.092% $ 23.3m | |
| Director of Investor Relations | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief People Officer | 3.08yrs | no data | no data | |
| Senior Vice President of Global Supplier Alliance | 5.75yrs | no data | no data |
7.4yrs
Average Tenure
57yo
Average Age
Experienced Management: RSMD.F's management team is seasoned and experienced (7.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Non-Executive Chairman | 6.58yrs | US$791.18k | 0.16% $ 39.6m | |
| CEO & Director | 7.42yrs | US$9.64m | 0.25% $ 63.7m | |
| Independent Director | 15yrs | US$329.98k | 0.0069% $ 1.7m | |
| Lead Independent Director | 7.08yrs | US$344.98k | 0.014% $ 3.5m | |
| Independent Non-Executive Director | 1.25yrs | US$133.17k | 0.00097% $ 245.8k | |
| Independent Director | 1.75yrs | US$288.17k | 0.0017% $ 425.7k | |
| Independent Director | 6.75yrs | US$332.98k | 0.0093% $ 2.4m | |
| Independent Director | 2.75yrs | US$314.98k | 0.0038% $ 967.9k |
6.7yrs
Average Tenure
61yo
Average Age
Experienced Board: RSMD.F's board of directors are considered experienced (6.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
ResMed Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ResMed Inc.
- Ticker: RSMD.F
- Exchange: OTCPK
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$25.339b
- Shares outstanding: 144.67m
- Website: https://www.resmed.com
Number of Employees
Location
- ResMed Inc.
- 9001 Spectrum Center Boulevard
- San Diego
- California
- 92123
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RMD | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 1995 |
| RME | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1995 |
| 0KW4 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 1995 |
| RMD | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jun 1995 |
| RMD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 1995 |
| RMD | ASX (Australian Securities Exchange) | CDI COM USD0.004 (10CDI/1SHS) | AU | AUD | Nov 1999 | |
| RSMD.F | OTCPK (Pink Sheets LLC) | CDI COM USD0.004 (10CDI/1SHS) | US | USD | Nov 1999 | |
| RMEA | DB (Deutsche Boerse AG) | CDI COM USD0.004 (10CDI/1SHS) | DE | EUR | Nov 1999 | |
| RMD | CHIA (Chi-X Australia) | CDI COM USD0.004 (10CDI/1SHS) | AU | AUD | Nov 1999 | |
| RMD | CHIA (Chi-X Australia) | CDI COM USD0.004 (10CDI/1SHS) | AU | AUD | Nov 1999 | |
| R1MD34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 4 REPR 1 COM | BR | BRL | Jan 2020 |
Biography
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/11 00:20 |
| End of Day Share Price | 2020/08/07 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.